Hamad Bin Khalifa University (HBKU) is a research-intensive institution based in Doha, Qatar, and a member of the Qatar Foundation for Education, Science, and Community Development. It serves as a central hub for the nation’s biomedical and pharmaceutical R&D through its specialized research institutes, most notably the Qatar Biomedical Research Institute (QBRI) and the College of Health and Life Sciences (CHLS).
HBKU focuses on translating academic discoveries into clinical applications, particularly in precision medicine, genomics, and high-prevalence diseases in the Middle East. The university operates a dedicated commercialization arm, the HBKU Research and Development Corporation, which manages a portfolio of over 85 patents and multiple biotech spin-offs. Its research ecosystem is supported by state-of-the-art core facilities in genomics, proteomics, and stem cell engineering.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Precision Medicine & Translational Research
SIZE & FINANCIALS
Employees:501-1000
Revenue:Undisclosed
Founded:2010
Ownership:nonprofit
Status:operating
FUNDING
Stage:Government Funded
Total Raised:Undisclosed
Investors:Qatar Foundation, Qatar Research, Development, and Innovation (QRDI) Council, Ministry of Defence (Qatar)
PIPELINE
Stage:Preclinical
Lead Drug Stage:Phase 2 (Partnered)
Modalities:Small molecule, mAb, Stem cell therapy, Biomarkers, AI-driven diagnostics
Active Trials:5
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Qatar Foundation
Subsidiaries:Qatar Biomedical Research Institute (QBRI), Qatar Computing Research Institute (QCRI), HBKU Research and Development Corporation, QABY Biotech (Spin-off), Rayyan Systems (Spin-off)
Key Partnerships:Harvard Stem Cell Institute (Stem cell biology and diabetes research), AFFiRiS AG (Parkinson's clinical trial evaluation), H. Lundbeck A/S (Diagnostic tools for neurodegenerative diseases), F. Hoffmann-La Roche Ltd (Biomedical research collaboration), Sidra Medicine (Clinical research and precision medicine), Hamad Medical Corporation (Clinical trial implementation)
COMPETITION
Position:Leader
Competitors:King Abdullah University of Science and Technology (KAUST), New York University Abu Dhabi, Weill Cornell Medicine-Qatar, Cleveland Clinic (Research arm)
LEADERSHIP
Key Executives:
Dr. Ahmad M. Hasnah - President
Dr. Omar El-Agnaf - Executive Director, QBRI
Dr. Nadir Yildirim - Executive Director of Innovation and Industrial Relations
Scientific Founders:Her Highness Sheikha Moza bint Nasser
Board Members:H.E. Sheikha Hind bint Hamad Al Thani (Chairperson), H.E. Mr. Mansoor bin Ebrahim Al Mahmoud (Minister of Public Health), Dr. Ahmad M. Hasnah
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Hamad Bin Khalifa University (HBKU). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.